Figure 4.
Mast cell deficiency improves the anti-tumor efficacy of anti-OX40 in syngeneic KPC allograft model
(A) Experimental design and (B) survival curves in orthotopic syngeneic model. All of the anti-OX40 treated mast cell-deficient KrasG12D;P53flox/flox;PDX-1-Cre (KPC) tumor-bearing mice achieved a long-term tumor free survival, p = 0.0061.
(C) BLI-IVIS images show the tumor size before treatment at week 1 after tumor implantation (top) and after treatment at week 4 (bottom).
(D) Longitudinal tumor growths of PDAC were quantified following the treatments and presented extremely significant effect (p < 0.0001) by Two-way independent ANOVA. (Black sets in C and D) Growth of KPC tumors implanted into wild-type mice injected with saline control. (Green sets in C and D) Growth of KPC tumors implanted into mast cell-deficient mice injected with saline control. (Blue sets in C and D) Growth of KPC tumors implanted into wild-type mice injected with agonist anti-OX-40. (Red sets in C and D) Growth of KPC tumors implanted into mast cell-deficient mice injected with agonist anti-OX-40.
(E) PDAC tumor growth (tumor sizes) curves in orthotopic syngeneic model. Data indicate fold change in photons/sec/cm2/sr ± standard deviation. The Bonferroni post hoc multiple comparisons showed significance between groups over time: black vs. green = 0.014; black vs. blue <0.0001; black vs. red <0.0001; green vs. blue = 0.944; green vs. red <0.0001; blue vs. red = 0.002. This experiment has been repeated more than 5 times using 5 mice in each group.